Propanc Biopharma, Inc.
PPCB
$1.87
-$0.08-4.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -10,165.29% | 26.39% | -0.97% | 52.06% | 34.96% |
| Total Depreciation and Amortization | 6.25% | -27.12% | 3.77% | 3.57% | -14.29% |
| Total Amortization of Deferred Charges | -27.05% | -19.60% | -17.99% | -26.96% | 51.02% |
| Total Other Non-Cash Items | 8,945,500.00% | -31.33% | 91.77% | -70.49% | -99.83% |
| Change in Net Operating Assets | -42.77% | 168.22% | -28.97% | -1,308.11% | 67.36% |
| Cash from Operations | -32.49% | 97.36% | 29.39% | -46.07% | 46.65% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 251.62% | -34.94% | -56.27% | -- | -41.16% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -88.00% | -93.66% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 181.53% | -70.87% | -38.42% | 151.00% | -75.29% |
| Foreign Exchange rate Adjustments | 48.12% | -327.33% | 139.41% | 559.62% | -266.25% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 155.20% | -91.69% | -247.06% | 117.91% | -195.06% |